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Although an influenza vaccine has been available for 70 years, influenza virus still
causes seasonal epidemics and worldwide pandemics. Currently available vaccines
elicit strain-specific antibody (Ab) responses to the surface haemagglutinin (HA) and
neuraminidase (NA) proteins, but these can be ineffective against serologically-distinct
viral variants and novel subtypes. Thus, there is a great need for cross-protective or
“universal” influenza vaccines to overcome the necessity for annual immunization against
seasonal influenza and to provide immunity to reduce the severity of infection with
pandemic or outbreak viruses. It is well established that natural influenza infection can
provide cross-reactive immunity that can reduce the impact of infection with distinct
influenza type A strains and subtypes, including H1N1, H3N2, H2N2, H5N1, and H7N9.
The key to generating universal influenza immunity through vaccination is to target
functionally-conserved regions of the virus, which include epitopes on the internal proteins
for cross-reactive T cell immunity or on the HA stem for broadly reactive Ab responses.
In the wake of the 2009 H1N1 pandemic, broadly neutralizing antibodies (bnAbs) have
been characterized and isolated from convalescent and vaccinated individuals, inspiring
development of new vaccination techniques to elicit such responses. Induction of
influenza-specific T cell responses through vaccination has also been recently examined
in clinical trials. Strong evidence is available from human and animal models of influenza
to show that established influenza-specific T cell memory can reduce viral shedding and
symptom severity. However, the published evidence also shows that CD8+ T cells can
efficiently select immune escape mutants early after influenza virus infection. Here, we
discuss universal immunity to influenza viruses mediated by both cross-reactive T cells
and Abs, the mechanisms of immune evasion in influenza, and propose how to counteract
commonly occurring immune-escape variants.
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INTRODUCTION
Immunization is the most cost effective public health measure to
prevent the spread of infectious diseases. Influenza causes sea-
sonal epidemics as well as periodic global pandemics due to the
introduction of novel strains and sporadic outbreaks from animal
reservoirs. During the 2009 H1N1 pandemic, the overall infection
rate was 10%, although the infection rate rose to 43% in school-
aged children (Wu et al., 2010). Yet, an influenza vaccine has been
available since the 1940’s.
Current influenza vaccines predominantly mediate protection
by eliciting neutralizing Ab responses to epitopes on the head
region of the virion surface glycoprotein, HA, and also to the
NA. The traditional trivalent influenza vaccine (TIV) is based on
either inactivated whole/subvirion virus or detergent-disrupted
virions, and is administered as an intramuscular injection to
elicit systemic Ab responses. Alternatively, the live attenuated
influenza vaccine (LAIV), is given intranasally. The LAIV vaccine
does not boost T cell immunity in adults (He et al., 2006), but
does improve protection by eliciting Ab responses locally in the
respiratory tract. Notably, LAIV in children is able to establish
influenza-specific T cell responses, possibly due to their naïve
infection status (He et al., 2006). Whilst LAIV has increased
protection compared to TIV (Monto et al., 2009), TIV has
much wider use due to a greater number of manufacturers and
constrained use of LAIV in the elderly and very young.
Originally, the influenza vaccine was a monovalent prepara-
tion, based on the common circulating strain of influenza A virus
(IAV) and was swiftly updated to include an influenza B virus
when these were recognized in the 1940’s. Since the 1970’s, a
trivalent vaccine has been used to provide coverage for H1N1,
H3N2, and influenza B virus, which now co-circulate. Even more
recently, in 2013, the vaccine has become available in a quadriva-
lent form incorporating both Victoria and Yamagata lineages of
influenza B. Thus, the number of vaccine strains has progressively
been increased from a single strain to four, to provide broader
protection and overcome the diversity of multiple influenza virus
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subtypes and lineages. Nevertheless, within each subtype or lin-
eage, constant antigenic drift gives rise to new and unpredictable
antigenic variants that are not necessarily represented in the vac-
cine. Mismatch between the vaccine strain, predicted on the basis
of antigenically novel isolates circulating in the previous winter
in the opposite hemisphere, and the actual strain that emerges
in the current winter can result in significant loss of vaccine
effectiveness.
The mechanism of action of current vaccines, which medi-
ate protection by induction of neutralizing Ab responses to the
rapidly changing head of the HA protein, renders it ineffective
after a few years at best, once all the antigenic regions on the
head of the HA have mutated in response to pre-existing Ab.
Inactivated vaccines are also very poor inducers of CD8+ T cell
responses, presumably because of inefficient uptake and priming
by appropriate antigen presenting cells (APCs). There is evidence
from animal models that TIV vaccination can actually inhibit
the induction of cross-reactive T cell responses (Bodewes et al.,
2011), which require active virus replication, resulting in a greater
susceptibility to subsequent infection by novel viruses such as
H5N1 (Bodewes et al., 2010). With an increased appreciation of
the immune response and its induction, it is time to consider
new vaccine approaches for seasonal influenza that additionally or
exclusively target functionally conserved regions of the influenza
virus, and may therefore provide some level of disease reduction
against serologically distinct emergent strains, even in a pandemic
context.
IAVs, whose ancestral host is aquatic birds, have spread to
many other species including domestic poultry, horses, swine,
humans, and even fruit bats. Although there are 17 different
distinct HA subtypes and 10 NA subtypes thus far identified
for IAVs, only H1N1 and H3N2, and previously H2N2, sub-
types have become endemic in humans causing continual human
transmission and seasonal epidemics. The introduction of other
novel subtypes, as exemplified by the H5N1, H7N9, and H10N8
strains, cause sporadic human infections and are not yet fully
adapted for efficient human-to-human transmission. The seg-
mented nature of the influenza virus genome facilitates reassort-
ment to generate novel hybrid viruses between influenza viruses
from different species, some of pandemic potential. Furthermore,
the error-prone viral RNA-dependent RNA polymerase, which
enables the generation of viral mutants, facilitates selection of
influenza viruses resistant to anti-viral drugs and immune effec-
tors. Thus, influenza is continually evolving and novel influenza
viruses from animal reservoirs can cause unpredictable outbreaks,
such as the most recent outbreaks from swine in the US (vari-
ant H3N2), poultry markets of China (H7N9) and Hong Kong
(H5N1), leaving us unprepared and unprotected. Furthermore,
H7N9 and H5N1 infections are highly lethal, with around 30 and
60% hospitalization-associated mortality, respectively. Therefore,
there is a dire need for a vaccine that is effective against a “moving
target,” influenza viruses.
CROSS-REACTIVE ANTIBODIES LEAD TO RENEWED
INTEREST IN B CELL VACCINES
The novel 2009 H1N1 pandemic virus (pH1N1-09) spread world-
wide within 4 months due to minimal specific Ab immunity
across the population. However, due to the novelty of the HA
protein in some cases infection or vaccination resulted in the
induction of novel broadly “neutralizing” antibody responses
(reviewed in Corti and Lanzavecchia, 2013), leading to a renewed
interest in developing the targets of theses Abs (summarized in
Table 1) for universal vaccines.
The HA glycoprotein on the influenza virion exists as a trimer
and dominates the surface of the virus. The amino acid sequence
shows 40–70% conservation between different HA subtypes (e.g.
H1 vs. H7) and greater than 80% between strains within a sin-
gle subtype (e.g. H1 strains). Subtype variation underlies the
classification of influenza viruses into two phylogenetic groups:
group 1 (H5, H2, H1) and 2 (H3, H7, H10). Each HA monomer
consists of two disulphide-linked polypeptide chains HA1 and
HA2 (Figures 1A,B). The majority of the HA1 chain goes to
make up the globular head of the molecule, which contains the
receptor-binding domain (RBD). The RBD is the primary tar-
get for nAb responses elicited by current vaccines, and therefore
random mutations that lead to single amino acid changes in
Ab binding sites in this domain are selected under pressure to
avoid further such Abs, resulting in the process of antigenic drift.
In some instances, amino acid changes that alter the glycosyla-
tion pattern in the head region can also influence Ab binding.
Some bnAbs have been isolated that recognize epitopes on the
HA head region, e.g. FE17 (Corti et al., 2010), S139/1 (Yoshida
Table 1 | Potential targets for a universal influenza vaccine and their limitations.
Protein Location Site targetted Function of Immune effector Possible role in influenza protection Escape
target possible
HA Virion surface HAI_ (head) Virus binding nAb Block HA binding Yes
Virion and cell surface HA2 (stem) Viral fusion Non-nAb Block HA maturation, Fc-mediated lysis No
NA Virion surface Sialidase Virus release Non-nAb Block NA cleavage and virus release Yes
M2 Infected cell surface M2
Ectodomain
Ion channel Non-nAb Block virus entry No
NP Infected cell surface Unknown RNP structure Non-nAb ADCC and complement mediated lysis Unknown
Infected cell Conserved
pMHC
RNP structure T cells (CD4+ and CD8+) T cell cytotoxicity reduces viral load Yes (limited)
All Infected cell Conserved
pMHC
Various T cells (CD4+ and CD8+) T cell cytotoxicity reduces viral load Yes (limited)
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FIGURE 1 | Broadly reactive HA-specific Abs can bind different
regions of the HA (A,B), which based on the sequence or
structural conservation of the region targeted by Abs can lead to
reactivity against otherwise highly divergent influenza viruses (C),
such as influenza A group 1 and group 2 and even influenza B
viruses. The cartoon depiction of the HA protein (A,B) is not to scale.
Group 1 and 2 phylogeny of influenza A HA (C) was adapted from
Corti and Lanzavecchia (2013).
et al., 2009), CH65 (Whittle et al., 2011), C05 (Ekiert et al.,
2012) (Figure 1). However, escape mutations in the HA1 can be
generated either at Ab binding sites or flanking residues after
several passages in vitro, thus limiting the use of head-specific
bnAbs.
The stem of the HA, which supports the globular head,
contains a hydrophobic fusion region which is situated at the
N-terminus of the HA2 chain. This region plays a crucial role dur-
ing viral entry into cells, allowing endosome escape of the viral
genome, and is functionally and structurally conserved across HA
subtypes and therefore not susceptible to drift. The stem contains
a number of epitopes spanning the fusion region, which are con-
served across different influenza subtypes (Okuno et al., 1993),
enabling the isolation of influenza-specific broadly cross-reactive
Abs capable of recognizing either group 1 HA (from Crucell
CR6261) (Ekiert et al., 2009), group 2 HA (CR8020) (Ekiert
et al., 2011), both group 1 and 2 HAs (FI6) (Corti et al., 2011),
or even recognize different influenza A and B strains (CR9114)
(Dreyfus et al., 2012) (reviewed in Corti and Lanzavecchia, 2013)
(Figure 1). One hypothesis for the induction of post-pandemic
group 1-specific stem Abs is that the pH1N1-09 virus displayed
a sufficiently distinct HA1 head domain when compared to the
pre-pandemic H1N1 viruses, that pre-existing memory B cells
specific for the HA head could not be recruited stem-specific
responses. Thus, H1N1-2009 virus exposure generated a primary
HA1-specific H1 Ab response but in addition was able to boost
the low frequency group 1 stem specific Abs (Corti et al., 2010;
Margine et al., 2013).
Importantly, HA2 stem-specific Abs prevent the conforma-
tional changes required for viral entry and membrane fusion,
thus mutational escape is not possible due to the critical function
and conserved helical structure of the stem. However, very high
concentrations of stem-specific Abs are often required to mediate
virus neutralizing activity, as they are 100–1000 times less potent
than HA head-specific Abs (Corti et al., 2010). Typically, stem-
specific Abs do not inhibit sialic acid binding by the receptor-
binding site, as do classical head-specific Abs. For this reason
they are unable to be identified by standard haemaglutination
inhibition (HAI) assays, and are measured by virus neutraliza-
tion or modified ELISA type assays. It should also be noted that
bnAbs often represent highly edited B cell receptor sequences
from germline requiring affinity maturation and co-ordination
with T follicular helper cells (reviewed in Corti and Lanzavecchia,
2013), and thus they are often very rare and of low frequency.
Advanced B cell cloning techniques have enabled the identifi-
cation and isolation of unique bnAbs (Corti et al., 2011) for
prophylactic and therapeutic use.
Vaccination with the conserved HA2 stem was first explored
as an Abs target nearly 30 years ago (Graves et al., 1983), and
is now receiving renewed attention in the wake of the 2009
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pandemic. Various methods have been employed by different
research groups to elicit bnAbs following exposure to influenza,
such as headless HA protein or virus exposing the stem (Steel
et al., 2010; Wang et al., 2010), prime-boost with a chimeric HA
(Krammer et al., 2013) or by sequential infection with differ-
ent influenza subtypes (Krammer et al., 2012) and DNA-prime
heterologous-boost vaccination (Wei et al., 2010). Furthermore,
bnAbs (CR6261, CH65, and scF10) have even been incorporated
directly into self-assembling nanoparticles, providing long-term
passive immunity in animal models (Kanekiyo et al., 2013), a
strategy that could potentially be beneficial for the elderly or
immunocompromised. Importantly, using the murine model it
has been recently elucidated that the protective effect of some
broadly-neutralizing stem-specific Abs is dependent on FcγR
interactions (DiLillo et al., 2014) so that their main activity is not
by classical neutralization of virus particles.
Other broadly reactive Abs that work in this way are
those directed to the highly conserved surface M2 ion channel
ectodomain (M2e). M2 is only expressed in very small amounts
on the virion surface but is present on the infected cell surface
where it can form a target for cross-reactive lytic responses. M2e-
specific Abs are induced only at very low frequency by influenza
infection, and are not elicited at all by the standard TIV vacci-
nation, although they can be induced by M2e-specific vaccines
(Neirynck et al., 1999; Mozdzanowska et al., 2003). Unexpectedly,
Abs specific for the viral nucleoprotein (NP), which surrounds
the genome, have also shown passive protection in mouse models
at very high doses (Carragher et al., 2008; Lamere et al., 2011) and
can be found in human serum (Sukeno et al., 1979). In vitro stud-
ies demonstrated that influenza-infected cells express low levels
of NP on their surface (Virelizier et al., 1977; Yewdell et al., 1981),
which may enable NP recognition by immune effectors, or alter-
natively, it is possible that NP-specific Abs are internalized and
interrupt virus replication. Utilization of non-neutralizing NP
and M2e Abs might be beneficial when combined with additional
protective immune mechanisms.
Abs that are not virus neutralizing may also function in
Ab-dependent cellular cytotoxicity (ADCC). pH1N1-09, H5N1-
specifc and NP-specific ADCC Abs have been found in the
absence of nAb responses in healthy individuals (Jegaskanda
et al., 2013b). Influenza infection, but not standard TIV vacci-
nation of macaques, elicited H1N1-specific ADCC Ab responses
(Jegaskanda et al., 2013a), thus future vaccines would need to be
optimized to elicit ADCC responses.
However, a forewarning comes from recent evidence in mouse
models, which showed that influenza virus was able to specif-
ically infect influenza-specific B cell receptor (BCR)-expressing
B cells leading to BCR editing, thus allowing establishment
of viral infection despite pre-existing Ab responses (Dougan
et al., 2013). There is also evidence from a swine vaccination
model that stem-specific HA2 Abs can enhance viral fusion and
increase immunopathology upon H1N1pdm infection (Khurana
et al., 2013). Therefore, while broadly cross reactive Abs are an
increasingly promising area for combating influenza infections
of distinct strains, their use should not be without investiga-
tion and should be used in conjunction with additional immune
mechanisms.
HETEROSUBTYPIC T CELL RESPONSES FOR INFLUENZA
CD8+ T cells recognize virus-derived peptides in the context
of class I major histocompatibility antigens (MHC-I). pMHC-
I is displayed on the surface of APCs enabling CD8+ T cell
priming and on virus-infected cells for CD8+ T cell effector func-
tion, thus infected cells can be killed before virus progeny is
released. The cytotoxic function is mediated mainly via the deliv-
ery of perforin and granzymes into the infected cell (Topham
et al., 1997) as well as by cytokine release (Marshall et al., 2005).
Thus, CD8+ T cell recognition of influenza viruses is only pos-
sible for an established infection, in contrast to sterilizing nAb
responses. However, CD8+ T cells are critical in the elimination of
influenza viruses, expediting viral clearance, and reducing pathol-
ogy. Seminal work from influenza challenge of healthy human
volunteers showed that increased T cell cytotoxicity was associ-
ated with reduced virus shedding (McMichael et al., 1983b), even
in volunteers lacking nAbs against the infecting virus. Moreover,
high levels of influenza-specific pre-existing memory T cells have
been associated with milder symptoms during pH1N1 infection
(Sridhar et al., 2013). There is no doubt that the current Ab-based
approach should be maintained, but the incorporation of an even
far-from-perfect T-cell-inducing vaccine (or vaccine component)
could still save millions of lives during a pandemic, as T cells
have the potential for much broader protection than bnAbs across
diverse subtypes of influenza A.
The phenomenon of heterosubtypic immunity refers to mem-
ory T cells generated by one subtype that can cross-react against
different IAV subtypes, despite wide differences in surface gly-
coproteins (Braciale, 1977; Kees and Krammer, 1984; Yewdell
et al., 1985; Askonas et al., 1988; Wahl et al., 2009). T cell het-
erosubtypic immunity is mainly due to the majority of T cells
recognizing immunogenic peptides derived primarily from highly
conserved internal influenza proteins (Elhefnawi et al., 2011). For
CD8+ T cells, 193 immunogenic peptides presented by 51 differ-
ent Human Leukocyte Antigen Class I (HLA-I) molecules have
been described to date for influenza viruses (www.iedb.org). The
majority of CD8+ T cell antigenic peptides are derived from well-
conserved internal proteins NP, M1, and PB1 (Assarsson et al.,
2008; Lee et al., 2008; Wu et al., 2011; Grant et al., 2013). T cell
cross-reactivity between different IAVs has been demonstrated
between H1N1, H3N2, H2N2, H5N1, H3N2v, and H7N9 sub-
types (Table 2) (Epstein, 2006; Kreijtz et al., 2008; Greenbaum
et al., 2009; Hillaire et al., 2013; Quinones-Parra et al., 2014;
Van De Sandt et al., 2014). Thus, influenza-specific T cells can
provide universal protection against influenza disease and are of
significant interest for the design of next generation vaccines.
The viral clearing role of heterosubtypic killer CD8+ T cells is
well established in animal models and human studies (Table 2).
In a primary infection of CD8+ T cell-deficient mice, influenza
virus clearance is delayed andmortality is increased (Bender et al.,
1992), while in the absence of B cells or Abs, CD8+ T cells can
provide protection against otherwise lethal influenza (Graham
and Braciale, 1997; Epstein et al., 1998). Furthermore, transfer of
influenza-specific CD8+ T cells provides heterosubtypic protec-
tion (Yap et al., 1978; Taylor and Askonas, 1986). Secondary recall
responses from pre-existing memory CD8+ T cells, established
by either influenza virus infection or vaccination (Flynn et al.,
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Table 2 | Key human studies on cell-mediated immunity against IAV.
References Virus(es) Description
McMichael et al., 1983b H1N1 Lymphocyte cytotoxic activity was associated with lower virus shedding in
individuals challenged with H1N1
Gotch et al., 1988 H3N2→H1N1 CD8+ T cell lines generated with H3N2 virus lyse target cells infected with
Vaccinia viruses encoding NP, M1, or PB2 proteins derived from H1N1
Epstein, 2006 H1N1→H2N2 Adults that contracted H1N1 influenza prior to the emergence of pH2N2-57 were
pronouncedly less susceptible to the pandemic virus
Kreijtz et al., 2008 H3N2→H5N1 CD8+T cell lines established with H3N2 cross-react with immunogenic peptides
derived from H5N1
Lee et al., 2008 Seasonal (s) IAV→H5N1 CD4+ and CD8+ T cells from H5 seronegative donors respond to peptides
spanning the H5N1 proteome
Assarsson et al., 2008 H1N1, H3N2, H2N2, H5N1, H7N7,
H6N1, H7N7, and H9N2
CD4+ and CD8+ T cells from healthy donors respond to substantially conserved
immunogenic peptides
Tu et al., 2010
sH1N1/sH3N2→pH1N1-09 Purified, influenza-specific memory CD8+ T cells expanded with sH1N1 and
sH3N2 recognize target cells infected with pH1N1-09
Gras et al., 2010 pH1N1-09→pH1N1-1918 B7-NP418-specific CD8+ T cells elicited by pH1N1-09 infection cross react with
the pH1N1-1918-NP418 variant
Wilkinson et al., 2012 H3N2 Pre-existing CD4+ T cell responses correlated with lower virus shedding and
disease severity upon challenge with H3N2 in seronegative volunteers
Fox et al., 2012 pH1N1-09 CD8+ T cell activation is delayed in patients severely infected with pH1N1-09 and
are lymphopenic for CD4+, CD8+ T cells, and NK cells
Zhao et al., 2012 pH1N1-09 Influenza-specific CD4+ T cells responses are associated with progression to
severe pH1N1-09 infection
Sridhar et al., 2013 pH1N1-09 Pre-existing memory CD8+ T cell responses from seronegative patients naturally
exposed to pH1N1-09 correlate with reduced illness severity
Hillaire et al., 2013 sH1N1/sH3N2→pH1N1-09/H3N2v CD8+ T cells lines generated with sH1N1, sH3N2 viruses or peptides derived
from these strains respond to target cells infected with pH1N1 virus
Van De Sandt et al., 2014 pH1N1/sH1N1/sH3N2→H7N9 CD8+ T cells stimulated with sH1N1, sH3N2, or pH1N1 recognize and lyse target
cells infected with H7N9
Quinones-Parra et al., 2014 Any human IAV including H7N9 CD8+ T cells from healthy donors expressing the HLA-A*0201, -A*0301,
-B*5701, -B*1801 allele, and/or B*0801 allele(s) respond to universally conserved
immunogenic peptides
1999) resulted in superior viral clearance and reduced pathol-
ogy (Flynn et al., 1998). Moreover, tertiary challenge of mice with
highly lethal H7N7 resulted in recall of heterosubtypic memory
CD8+ T cell responses (established from priming with H1N1 and
then H3N2) that provided exceptionally enhanced virus control
(within 3 days post-infection) (Christensen et al., 2000).
In comparison to CD8+ T cells, the role of CD4+ T cells in
influenza is less well understood, partly due to their heterogene-
ity and the lack of epitope-specific systems (Sant and McMichael,
2012). The traditionally accepted role of influenza-specific CD4+
T cells is in providing help to B cells for the production of high-
quality Abs (Topham and Doherty, 1998), as their activation is
dependent on recognition of peptide in the context of MHC-II
on professional APCs but also have a major role in providing help
for the establishment of CD8+ T cell memory, critical for a robust
recall response (Sun et al., 2004). Transfer of influenza-specific
effector CD4+ T cells into T cell-deficient mice accelerates pro-
duction of neutralizing Abs, thus cross-reactive memory CD4+
T cells can potentially enhance B cell responses during infec-
tion with a novel influenza virus (Scherle and Gerhard, 1986).
Furthermore, depletion of CD4+ T cells prior to influenza chal-
lenge results in a dramatic drop of Ab titres (Eichelberger et al.,
1991), accompanied by only a small delay in virus elimination
(Allan et al., 1990), driven by the remaining CD8+ T cell response
(Topham et al., 1996; Belz et al., 2002). More recently, a com-
prehensive transgenic mouse study by McKinstry et al. (2012)
illustrated the direct protective role of influenza-specific CD4+
T cells using a series of transfer experiments into immune knock-
out mice (lacking FcRγ, functional IFNγ, or B cells). The authors
showed that CD4+ T cells provide protection by interacting
with B cells and CD8+ T cells in an IFN-γ-dependent manner.
The mechanism by which CD4+ T cells are able to recognize
virus-infected cells given their MHC-II restriction is yet to be
deciphered. Nevertheless, in a vaccination setting of individuals
receiving a split vaccine, a subset (ICOS+CXCR3+CXCR5+) of
circulating influenza-specific CD4+ T follicular helper (TFH) cells
correlated with more effective B-cell responses and greater Ab
titres, suggesting that eliciting this type of cells could be impor-
tant in inducing more effective Ab-based vaccines (Bentebibel
et al., 2013).
The debate of which T cell subtype is more protective for
influenza has been reinvigorated from recent human studies that
show contrasting results (Wilkinson et al., 2012; Zhao et al., 2012;
Sridhar et al., 2013). However, as evidenced from mouse studies
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outlined above, both subsets are necessary for a complete and
coordinated response against influenza infection. Interestingly,
in a challenge study (Wilkinson et al., 2012) with volunteers
deliberately infected with H3N2, the numbers of pre-existing
influenza-specific CD4+, but not CD8+, T cells were found to
correlate with lower virus shedding and less severe, shorter ill-
ness. These investigators favored CD4+ T cell cytotoxicity as the
possible underlying mechanism. However, in a later study inves-
tigating T cell immunity in H1N1pdm virus-infected patients,
CD4+ T cell responses were associated with more severe infec-
tion (Zhao et al., 2012). A more recent study (Sridhar et al., 2013)
followed natural infection of a large cohort over the 2009 pan-
demic and determined pre-immune correlates with the outcome
of influenza disease over the pandemic. The study showed that
those individuals with established influenza-specific CD8+ T cell
memory experienced milder illness following infection with the
newly emerged virus. Although this study did not find a correla-
tion with CD4+ T cell responses and disease outcome, it cannot
rule out their importance. Further studies are needed to bet-
ter understand immune mechanisms underlying T cell-mediated
protection against influenza viruses.
Some experimental vaccination protocols have effectively
induced protective heterosubtypic T cell immunity, including
non-replicative, cold adapted influenza vaccine (Powell et al.,
2007), and virus-like particles (Hamada et al., 2013). In addition,
DNA vaccines (Ulmer et al., 1993, 1998; Fu et al., 1999), prime-
boost protocols (Epstein et al., 2005) and the use of adjuvants
can provide and enhance T cell-mediated heterosubtypic pro-
tection (Chua et al., 2011, 2014). A live non-replicating vaccinia
vaccine encoding the NP and M1 proteins, MVA-NP/M1, is cur-
rently being evaluated in human efficacy trials (Berthoud et al.,
2011). The vaccine proved effective for human influenza chal-
lenge in a limited number of individuals, showing higher levels
of influenza-specific CD8+ T cells in vaccinees, especially those
displaying the HLA-A∗0201 allele, compared to placebo controls
correlating with reduced infection and viral shedding (Antrobus
et al., 2012; Lillie et al., 2012). Furthermore, the vaccine was able
to boost T cell immunity in those aged 65 and over, a promising
result for those who need an effective vaccine the most. However,
it may be difficult to convince regulatory authorities to license a T
cell-based vaccine that still allows individuals to become infected
and shed virus. If such a vaccine were to replace the current TIV, a
large-scale study would need to be performed inmany individuals
of distinct HLAs across different ethnicities to prove effectiveness.
Thus, manipulating existing style vaccines to induce or boost
T cell immunity could potentially lead toward development of
broadly protective influenza vaccines. However, there are still con-
siderable challenges in the development of broadly cross-reactive
T cell-inducing vaccines, which include persistence of T cell
memory after influenza immunization (Valkenburg et al., 2012),
population protective coverage across different HLAs, vaccine-
mediated immune escape and immunopathology. Firstly, it is still
far from clear for how long functional influenza-specific memory
CD8+ T cells persist in humans. Studies from yellow fever and
smallpox vaccination suggest that memory T cells can be detected
from 10 years (Akondy et al., 2009) to 50 years (Miller et al., 2008)
following vaccination, respectively. Yet many adults fail to control
influenza infection. A vaccine study of young children found that
a threshold level (of >100 SFU/106 PBMCs) was required for
effective T cell-mediated clinical protection (Forrest et al., 2008).
Therefore, the varying levels of T cell immunity that are likely
to exist in the wider population, due to different histories of
exposure to natural infection, may contribute to the spectrum of
disease severity. Early studies on cytotoxic T cells in humans sug-
gested that influenza CTL memory declines rapidly with a half
life of 2–3 years (McMichael et al., 1983a). The main purpose of
a T cell-inducing vaccine may therefore be to maintain memory
CD8+ T cells at levels capable of achieving clinical protection,
which may require booster doses every few years. The presence
of co-morbidities, age-related differences of innate responses in
the young and immunological decline in the elderly (reviewed
by Oshansky and Thomas, 2012) could also impair T cell recall
responses. Furthermore, an influenza T-cell based vaccine would
have to address the issue HLA coverage in a diverse population
and be appropriate for ethnic minorities with rare MHC alleles.
This could be achieved either by utilization of peptide epitopes
representing HLA-super families (Assarsson et al., 2008), or the
inclusion of full-length influenza-derived proteins in a form that
enables endogenous antigen processing.
INFLUENZA CAN ESCAPE T CELL IMMUNITY
If such a T cell-inducing vaccine could be produced, the issue of
vaccine-mediated T cell escape, resonant of Ab-mediated anti-
genic drift, could theoretically become significant. RNA viruses,
such as influenza, are characterized by poor fidelity of replication
of their genomes, leading to the emergence of viral variants capa-
ble of rapidly adapting in response to immune selective pressure,
as seen with seasonal antigenic drift. Subversion of T cell con-
trol is well documented for chronic viral infections, like HIV and
HCV (Pircher et al., 1990; Moore et al., 2002; Fernandez et al.,
2005) and represents one of the major obstacles for viral control
and vaccine design.
Within an individual, T cells can select influenza escape vari-
ants as the virus replicates. We have recently described the emer-
gence of influenza variants within CD8+ T cell target regions in
a persistently infected, immunocompromised child, (Valkenburg
et al., 2013). Additionally, CD8+ T cell immune escape viruses
could be readily isolated from immunodeficient (B cell knockout)
and immune intact wild-type mice. Surprisingly, we observed
that these CTL escape variants arise early during infection by
day 5, and increase in frequency and variety over the time-
course of infection. The selection of CD8+ T cell escape mutants
was clearly driven by selective pressure as these variants revert
in the absence of immune pressure in MHC-mismatched mice
(Valkenburg et al., 2013). Further experiments suggested that
influenza-specific escape from T cell responses is heavily depen-
dent on the particular epitope and potentially the underlying
characteristics of the T cell receptor repertoire. Interestingly,
influenza viruses favored escape at the residues that anchor epi-
tope peptides to MHC (Valkenburg et al., 2013).
The emergence of specific CD8+ T cell mutations in influenza
can also be detected at a population level. Factors such as immun-
odominance, HLA frequency and viral fitness can impact the
likelihood of emergence and selection of escape viruses (Berkhoff
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et al., 2005). Indeed, there are documented examples of natu-
rally occurring mutations within critical T cell antigenic peptides
leading to immune escape in individuals bearing certain HLA
alleles. The Rimmelzwann group has pioneered and enhanced
our knowledge of CD8+ T cell-mediated immune escape in
human influenza. Boon et al. (2004) identified substitutions
within the HLA-B∗0702- and B∗3501-restricted NP418–426 epi-
tope that could either result in cross-reactivity, or in some cases, in
immune escape. Further immunological and structural character-
ization of the NP418–426 variants from 1918 to 2009 revealed that
mutations in solvent-exposed, potentially TCR contact residues,
result in immune escape (Gras et al., 2010). At the same time,
we confirmed the presence of cross-reactive CTL populations that
reacted against a wider spectrum of NP418–426 variants (Gras
et al., 2010). The identification of epitopes recognized by such
populations, and the key residues for TCR recognition within
them,may be critical information for producing a vaccine capable
of eliciting cross-reactive T cells to provide coverage against the
wide spectrum of influenza antigenic variation, an idea that we
have pioneered using the B6 mouse model of influenza infections
(Valkenburg et al., 2013). Conversely, CD4+ T cell-mediated viral
escape in influenza has received considerably less attention and
the selection of CD4+ T cell escape peptide variants has not cur-
rently been demonstrated, either within an individual or across a
population.
In earlier work examining drift in the viral NP at a population
level, Voeten et al. (2000) identified mutations in HLA-B∗2705-
restricted NP383–391 epitope and HLA-B∗08:01-NP380–388 result-
ing in immune escape. The NP-R384K mutation at an MHC-I
anchor residue, which resulted in a loss of CD8+ T cell recogni-
tion, was initially detected in 1990 and later in 1993 as R384G.
The escape mutant quickly replaced the wild-type sequence in
H3N2 viruses (Gog et al., 2003), resulting in a loss of immuno-
genicity in the population expressing the HLA-B27 allele. Further
characterization of this mutant indicated that the escape was
driven by CTL selective pressure as the mutation imposed a
fitness cost that had to be compensated for by additional muta-
tions in flanking regions (Rimmelzwaan et al., 2005). More
recently, a CTL escape variant within the HLA-A∗0101-restricted
NP44–52 in the novel H7N9 virus has been reported (Quinones-
Parra et al., 2014; Van De Sandt et al., 2014), with structural
data indicating that substitution in an MHC-I anchor residue
of the peptide epitope compromised peptide-MHC-I complex
stability and thus accessibility to CTLs (Quinones-Parra et al.,
2014).
Although immunodominant T cells may generate escape vari-
ants, they remain a hugely valuable tool in the arsenal for com-
bating influenza infection. It may be possible to pre-empt escape
by priming the T cell repertoire against a variety of dominant
mutants at TCR contact sites (Valkenburg et al., 2013) or pos-
sibly stabilizing the MHC for low affinity anchor mutants. The
NP protein, though capable of harboring T cell escape mutations,
is one of the most immunogenic influenza proteins for T cells
(Grant et al., 2013). Fortunately, the NP of LAIV can be substi-
tuted to represent the current NP or the NP of escape variants
without affecting the viral growth or vaccine immunogenicity
(Isakova-Sivak et al., 2011).
INNATE T CELLS FOR INFLUENZA VIRUS INFECTION
Until now this review has discussed adaptive immunity to
influenza, however another component, innate T cells, have
potential use for subverting infection due to innate receptors
recognizing conserved universal motifs. The non-conventional
or innate T cell compartment comprises of γδ T cells, CD1d-
restricted invariant natural killer T cells (iNKT), and MR1-
restricted Mucosal-associated invariant T (MAIT) cells. This
compartment constitutively expresses high levels of the C-type
lectin, CD161. Innate T cells can be activated by a diverse range
of ligands, either endogenous (β-GlcCer and iGB3 for NKT;
MICA/B for γδ T cells) and exogenous (phosphoantigens and bis-
phosphonates for γδ T cells, α-GalCer-for iNKT, bacterial lipids
for NKT and metabolites for MAIT cells) (Kjer-Nielsen et al.,
2012; Rossjohn et al., 2012; Born et al., 2013). Upon TCR recogni-
tion of their cognate antigen or by cytokine driven signals, innate
T cells can rapidly produce an array of inflammatory and effec-
tor molecules (IFNγ, TNF, IL-17, IL-4, IL-22, perforin, granzyme
B, MIP-1β). In humans, innate T cells can comprise up to 30%
of the peripheral blood CD3+ T cell compartment, and are also
enriched atmucosal sites including lung, intestine and liver. Given
their location, potent inflammatory and cytolytic function, innate
T cells are potentially important players during IAV infection.
Although their role is well studied in autoimmunity, cancer, and
chronic viral infections such as HIV-1, (Berzins et al., 2011;
Cosgrove et al., 2013; Leeansyah et al., 2013; Vantourout and
Hayday, 2013), there is a paucity of data on how innate T cells
contribute to combating influenza infection.
Several studies in humans have demonstrated that a major
subset of human γδ T cells (Vγ9Vδ2) can directly kill human
and avian origin influenza-infected macrophages and lung alve-
olar epithelial cells in vitro (Qin et al., 2009; Tu et al., 2011; Li
et al., 2013). Further studies in humanized mice have shown that
vaccination with aminobisphosphonate pamidronate (PAM) can
activate the Vγ9Vδ2 subset, and that Vγ9Vδ2 T cells can inhibit
viral replication and dampen inflammatory responses in the lung
(Tu et al., 2011). Thus, pre-arming γδ T cells may also be bene-
ficial in human IAV infection as an alternative antiviral strategy
(Tu et al., 2011).
Similarly, endogenous iNKT cells have been shown to have an
immunoregulatory role in IAV. From adoptive transfer studies
in C57BL/6 mice, iNKT cells have been demonstrated to allevi-
ate bronchopneumonia and its associated pathology in Jα18−/−
(iNKT deficient) mice infected with highly virulent H3N2 (Paget
et al., 2011; Kok et al., 2012). Both endogenous and exoge-
nous (α-GalCer) activation of iNKT aids in the development
of influenza-specific CD8+ T cells by promoting their survival
(Guillonneau et al., 2009) and the maturation of APCs that
present epitopes to influenza-specific CD8+ T cells (Paget et al.,
2011). Additionally, iNKT-derived cytokines, such as IL-33 and
IL-22, produced during IAV infection have been associated with
regulation of eosinophil maturation in an IL-5-dependent man-
ner and protection of the airway epithelium, respectively (Paget
et al., 2012; Gorski et al., 2013). These studies demonstrate that
iNKT can aid in the maturation of both the influenza-specific
adaptive and the innate response, and therefore may be important
subsets to induce in a universal IAV vaccine.
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Although the majority of these studies highlight the
immunoregulatory role of murine innate T cells in models of
IAV, more studies are needed in humans to investigate whether
these and other non-conventional innate T cells may contribute
to influenza-specific adaptive immune effectors and thus be of
benefit to induce in a universal IAV vaccine.
CONCLUSIONS
Although the current Ab-mediated vaccines are the most cost
effective way to combat the yearly influenza epidemics, they
are strain-specific and thus need to be updated annually while
providing little or no protection from novel outbreak strains.
Furthermore, during the 2009 pandemic, it took several months
to produce and test the newly made H1N1pdm-specific influenza
vaccine, which meant it was only available after the peak of
influenza activity. Thus, there is an urgent need to develop novel
approaches for a universal influenza vaccine that has broad reac-
tivity across a diversity of influenza strains and subtypes. Ideally,
this vaccine would elicit both broadly cross-reactive Abs directed
at highly conserved yet sub-dominant targets such as the HA
stalk, which are currently proving highly effective in mouse stud-
ies. Furthermore, the ideal vaccine would also elicit a robust
T cell response with long-term memory potential, recognizing
epitopes derived from conserved and immunogenic internal pro-
teins. Recent data on both universal Abs and T cell responses
against influenza are promising, but more research still needs to
be done to provide insights into the longevity and effectiveness
of this type of immunity. The possibility of generating escape
mutants by widespread use of vaccines designed to elicit such
cross-reactive responses needs to be understood as well as the
potential impact on virus evolution.
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